Study Protocol: Efficacy of Jintiange Capsule in Lumbar Disc Herniation: A Single‐Center, Randomized Controlled Trial
4 affiliations
- 1The First Affiliated Hospital of Anhui University of Chinese Medicine Hefei China ahtcm.edu.cn
- 2Anhui University of Chinese Medicine Hefei China ahtcm.edu.cn
- 3Wangjing Hospital China Academy of Chinese Medical Sciences Beijing China cacms.ac.cn
- 4Xiyuan Hospital China Academy of Chinese Medical Sciences Beijing China cacms.ac.cn
Abstract
Background: Lumbar disc herniation (LDH) is a leading cause of chronic low back pain (LBP), severely impairing patients’ quality of life and imposing a substantial global socioeconomic burden. Conservative treatment remains the first‐line clinical option, but the commonly prescribed drug celecoxib carries a risk of gastrointestinal bleeding or perforation. Traditional Chinese medicine preparations have been proposed as alternatives, although current evidence is insufficient. Jintiange (JTG) capsule, developed as a substitute for tiger bone, exerts its pharmacological effects by inhibiting osteoclastogenesis and regulating the NF‐κB pathway. Previous studies have identified a close association between the p38MAPK/NF‐κB pathway and pain induced by LDH. However, the efficacy of JTG in treating LDH remains unclear. High‐quality research is thus urgently needed to provide evidence‐based support for its clinical application.
Method: This randomized, single‐center clinical trial will enroll 68 participants, centrally allocated 1:1 to receive either JTG capsules plus comprehensive Western medicine (celecoxib + eperisone) or Western medicine alone. All participants will complete an 8‐week treatment phase (celecoxib for 2 weeks + eperisone for 8 weeks; with JTG capsules added for 8 weeks in the experimental group), with a follow‐up at Week 12 (4 weeks after treatment completion). The primary outcome is the change in the Japanese Orthopaedic Association (JOA) score for LBP, a validated instrument for evaluating treatment efficacy in LDH. Secondary outcomes include the Patient Global Impression of Change (PGIC), Visual Analog Scale (VAS) score, SF‐12 quality‐of‐life score, and elastic modulus of the lumbar muscles. Safety monitoring and adverse‐event recording will occur throughout the study. The primary endpoint will be analyzed using the analysis of covariance. Longitudinal VAS scores at Weeks 2, 8, and 12 will be analyzed using a mixed model for repeated measures. PGIC will be analyzed as an ordinal categorical outcome, while other secondary outcomes will be analyzed using appropriate parametric or nonparametric methods. All analyses will be performed using SPSS 28.0, with no interim analysis planned.
Discussion: This trial will evaluate the clinical efficacy of JTG capsules combined with Western medicine for LBP and will explore its safety profile as a secondary/exploratory endpoint. Given the open‐label combination design, safety findings will be interpreted with caution, and causality attribution to JTG alone will be limited. The findings are expected to provide an evidence‐based treatment option, supporting the potential role of Chinese patent medicine in LBP management.
Trial Registration: Chinese Registry of Clinical Trials: ChiCTR2300069735
Related
- Jintiange capsule as add-on therapy for lumbar disc herniation: an open-label randomized controlled trial
- Efficacy of a smartphone digital therapeutic (re-R) for post-total knee arthroplasty rehabilitation: study protocol for a single-center randomized controlled trial in the Republic of Korea
- Efficacy and neural mechanisms of transcutaneous auricular vagus nerve stimulation for chronic insomnia: a study protocol for a randomized controlled trial
- Efficacy of a personalized, response-based transdiagnostic intervention for emotional disorders delivered via the Internet: a protocol for an adaptive randomized controlled trial
- Efficacy and safety of sivelestat sodium hydrate adjunct to remifentanil for analgesia in patients under mechanical ventilation (SIDING trial): protocol of a multicenter, randomized, double-blinded, placebo-controlled trial
BibTeX
@article{zhu2026study,
title = {{Study Protocol: Efficacy of Jintiange Capsule in Lumbar Disc Herniation: A Single‐Center, Randomized Controlled Trial}},
author = {Yinghao Zhu and Hao Lv and Yi Wang and Xunlu Yin and Kaiming Li and Hengtong He and Tianlin Wang and Long Liang},
journal = {Pain Research \& Management},
year = {2026},
month = oct,
doi = {10.1155/prm/4091533},
url = {https://doi.org/10.1155/prm/4091533},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Study Protocol: Efficacy of Jintiange Capsule in Lumbar Disc Herniation: A Single‐Center, Randomized Controlled Trial
AU - Yinghao Zhu
AU - Hao Lv
AU - Yi Wang
AU - Xunlu Yin
AU - Kaiming Li
AU - Hengtong He
AU - Tianlin Wang
AU - Long Liang
PY - 2026
DA - 2026/10/29
JO - Pain Research & Management
DO - 10.1155/prm/4091533
UR - https://doi.org/10.1155/prm/4091533
AB - Background: Lumbar disc herniation (LDH) is a leading cause of chronic low back pain (LBP), severely impairing patients’ quality of life and imposing a substantial global socioeconomic burden. Conservative treatment remains the first‐line clinical option, but the commonly prescribed drug celecoxib carries a risk of gastrointestinal bleeding or perforation. Traditional Chinese medicine preparations have been proposed as alternatives, although current evidence is insufficient. Jintiange (JTG) capsule, developed as a substitute for tiger bone, exerts its pharmacological effects by inhibiting osteoclastogenesis and regulating the NF‐κB pathway. Previous studies have identified a close association between the p38MAPK/NF‐κB pathway and pain induced by LDH. However, the efficacy of JTG in treating LDH remains unclear. High‐quality research is thus urgently needed to provide evidence‐based support for its clinical application. Method: This randomized, single‐center clinical trial will enroll 68 participants, centrally allocated 1:1 to receive either JTG capsules plus comprehensive Western medicine (celecoxib + eperisone) or Western medicine alone. All participants will complete an 8‐week treatment phase (celecoxib for 2 weeks + eperisone for 8 weeks; with JTG capsules added for 8 weeks in the experimental group), with a follow‐up at Week 12 (4 weeks after treatment completion). The primary outcome is the change in the Japanese Orthopaedic Association (JOA) score for LBP, a validated instrument for evaluating treatment efficacy in LDH. Secondary outcomes include the Patient Global Impression of Change (PGIC), Visual Analog Scale (VAS) score, SF‐12 quality‐of‐life score, and elastic modulus of the lumbar muscles. Safety monitoring and adverse‐event recording will occur throughout the study. The primary endpoint will be analyzed using the analysis of covariance. Longitudinal VAS scores at Weeks 2, 8, and 12 will be analyzed using a mixed model for repeated measures. PGIC will be analyzed as an ordinal categorical outcome, while other secondary outcomes will be analyzed using appropriate parametric or nonparametric methods. All analyses will be performed using SPSS 28.0, with no interim analysis planned. Discussion: This trial will evaluate the clinical efficacy of JTG capsules combined with Western medicine for LBP and will explore its safety profile as a secondary/exploratory endpoint. Given the open‐label combination design, safety findings will be interpreted with caution, and causality attribution to JTG alone will be limited. The findings are expected to provide an evidence‐based treatment option, supporting the potential role of Chinese patent medicine in LBP management. Trial Registration: Chinese Registry of Clinical Trials: ChiCTR2300069735
SN - 1203-6765
SN - 1918-1523
ER -